Abstract
Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.
| Original language | English |
|---|---|
| Pages (from-to) | 1266-1274 |
| Number of pages | 9 |
| Journal | Bone Marrow Transplantation |
| Volume | 54 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Transplantation
Cite this
A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma. / on behalf of ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.
In: Bone Marrow Transplantation, Vol. 54, No. 8, 01.08.2019, p. 1266-1274.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma
AU - on behalf of ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Yoshimitsu, Makoto
AU - Utsunomiya, Atae
AU - Fuji, Shigeo
AU - Fujiwara, Hiroshi
AU - Fukuda, Takahiro
AU - Ogawa, Hiroyasu
AU - Takatsuka, Yoshifusa
AU - Ishitsuka, Kenji
AU - Yokota, Akira
AU - Okumura, Hirokazu
AU - Ishii, Kazuyoshi
AU - Nishikawa, Akinori
AU - Eto, Tetsuya
AU - Yonezawa, Akihito
AU - Miyashita, Kaname
AU - Tsukada, Junichi
AU - Tanaka, Junji
AU - Atsuta, Yoshiko
AU - Kato, Koji
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.
AB - Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.
UR - http://www.scopus.com/inward/record.url?scp=85058470243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058470243&partnerID=8YFLogxK
U2 - 10.1038/s41409-018-0400-5
DO - 10.1038/s41409-018-0400-5
M3 - Article
C2 - 30546068
AN - SCOPUS:85058470243
VL - 54
SP - 1266
EP - 1274
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 8
ER -